Low-intensity regimens <i>versus</i> standard-intensity induction strategies in acute myeloid leukemia.

57 These results were not confirmed in a phase III randomized trial when the volasertib/LDAC arm was associated with a negative trend in OS and a significantly higher incidence of adverse events compared with LDAC alone (Dohner and colleagues 50 , European Haematology Association meeting, 2016).

also in 4,201 other papers

A significantly higher rate of cardiac toxicity and a nonsignificant trend toward higher pulmonary toxicity were observed in older patients, though there was no excess early mortality.

also in 5,406 other papers